Importantly, a significant fraction of those genes was changed in a direction that suggests decrease in doxorubicin-mediated inhibition of the aryl hydrocarbon receptor signaling, a pathway known to drive breast cancer progression. The gene discussed is AHR; the disease is breast carcinoma.